儿科指南

订阅

MedSci主页 / 所有栏目 / 儿科指南

中国儿童维生素A、维生素D临床应用专家共识

2020-12-10 中华预防医学会 中国儿童保健杂志.2021.29(1):131-138.

维生素D维生素A

维生素A和维生素D是与儿童健康密切相关的两种脂溶性维生素,充足的维生素A、维生素D营养对儿童早期发展及疾病的防治具有积极的作用,缺乏和不足均会影响儿童健康。针对儿童保健医生和儿童家长对维生素A、维生素

中文标题：

中国儿童维生素A、维生素D临床应用专家共识

发布机构：

中华预防医学会

发布日期：

2020-12-10

简要介绍：

维生素A和维生素D是与儿童健康密切相关的两种脂溶性维生素,充足的维生素A、维生素D营养对儿童早期发展及疾病的防治具有积极的作用,缺乏和不足均会影响儿童健康。针对儿童保健医生和儿童家长对维生素A、维生素D的营养现状、缺乏原因及危害、防治措施、安全性等方面所存在的一些疑虑,中华预防医学会儿童保健分会组织国内相关专家,就上述问题结合国内外相关研究展开了充分讨论,基于现有研究成果,达成如下共识,希望对我国儿童维生素A、维生素D的临床应用提供参考。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国儿童维生素A_维生素D临床应用专家共识_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4c7521c002031800, title=中国儿童维生素A、维生素D临床应用专家共识, enTitle=, guiderFrom=中国儿童保健杂志.2021.29(1):131-138., authorId=0, author=, summary=维生素A和维生素D是与儿童健康密切相关的两种脂溶性维生素,充足的维生素A、维生素D营养对儿童早期发展及疾病的防治具有积极的作用,缺乏和不足均会影响儿童健康。针对儿童保健医生和儿童家长对维生素A、维生素, cover=https://img.medsci.cn/20201230/1609257849588_2020535.jpg, journalId=0, articlesId=null, associationId=174, associationName=中华预防医学会, associationIntro=中华预防医学会是全国公共卫生预防医学领域的科技工作者自愿组成并依法在民政部登记注册的非营利性、公益性、学术性法人社团，是全国性学术团体，是发展我国预防医学科学技术和预防医学事业的重要社会力量。, copyright=0, guiderPublishedTime=Thu Dec 10 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>维生素A和维生素D是与儿童健康密切相关的两种脂溶性维生素,充足的维生素A、维生素D营养对儿童早期发展及疾病的防治具有积极的作用,缺乏和不足均会影响儿童健康。针对儿童保健医生和儿童家长对维生素A、维生素D的营养现状、缺乏原因及危害、防治措施、安全性等方面所存在的一些疑虑,中华预防医学会儿童保健分会组织国内相关专家,就上述问题结合国内外相关研究展开了充分讨论,基于现有研究成果,达成如下共识,希望对我国儿童维生素A、维生素D的临床应用提供参考。&nbsp;</p> </div> </div> </div>, tagList=[TagDto(tagId=1212, tagName=维生素D), TagDto(tagId=10984, tagName=维生素A)], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1313, guiderKeyword=维生素, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13194, appHits=681, showAppHits=0, pcHits=3924, showPcHits=12512, likes=9, shares=121, comments=38, approvalStatus=1, publishedTime=Wed Dec 30 00:24:21 CST 2020, publishedTimeString=2020-12-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Dec 30 00:04:14 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:41:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国儿童维生素A_维生素D临床应用专家共识_.pdf)])
中国儿童维生素A_维生素D临床应用专家共识_.pdf
下载请点击：
评论区 (29)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1216104, encodeId=ec1012161042b, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4481591542, createdName=wangaihua5399, createdTime=Sun May 01 18:40:50 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198861, encodeId=52fa1198861c7, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43525709658, createdName=ms6000000691333283, createdTime=Wed Mar 02 21:28:48 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189309, encodeId=8ea311893093c, content=积分不足了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41bf6155524, createdName=ms6000001446270839, createdTime=Sun Jan 30 16:06:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079362, encodeId=0a6410e936210, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:11:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078737, encodeId=421c10e8737c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d36395355, createdName=ms8000000249038546, createdTime=Fri Dec 10 11:59:25 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2022-05-01 wangaihua5399

    非常实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1216104, encodeId=ec1012161042b, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4481591542, createdName=wangaihua5399, createdTime=Sun May 01 18:40:50 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198861, encodeId=52fa1198861c7, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43525709658, createdName=ms6000000691333283, createdTime=Wed Mar 02 21:28:48 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189309, encodeId=8ea311893093c, content=积分不足了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41bf6155524, createdName=ms6000001446270839, createdTime=Sun Jan 30 16:06:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079362, encodeId=0a6410e936210, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:11:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078737, encodeId=421c10e8737c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d36395355, createdName=ms8000000249038546, createdTime=Fri Dec 10 11:59:25 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2022-03-02 ms6000000691333283

    关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1216104, encodeId=ec1012161042b, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4481591542, createdName=wangaihua5399, createdTime=Sun May 01 18:40:50 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198861, encodeId=52fa1198861c7, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43525709658, createdName=ms6000000691333283, createdTime=Wed Mar 02 21:28:48 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189309, encodeId=8ea311893093c, content=积分不足了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41bf6155524, createdName=ms6000001446270839, createdTime=Sun Jan 30 16:06:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079362, encodeId=0a6410e936210, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:11:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078737, encodeId=421c10e8737c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d36395355, createdName=ms8000000249038546, createdTime=Fri Dec 10 11:59:25 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2022-01-30 ms6000001446270839

    积分不足了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1216104, encodeId=ec1012161042b, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4481591542, createdName=wangaihua5399, createdTime=Sun May 01 18:40:50 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198861, encodeId=52fa1198861c7, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43525709658, createdName=ms6000000691333283, createdTime=Wed Mar 02 21:28:48 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189309, encodeId=8ea311893093c, content=积分不足了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41bf6155524, createdName=ms6000001446270839, createdTime=Sun Jan 30 16:06:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079362, encodeId=0a6410e936210, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:11:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078737, encodeId=421c10e8737c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d36395355, createdName=ms8000000249038546, createdTime=Fri Dec 10 11:59:25 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2021-12-13 福尔摩妮

    厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1216104, encodeId=ec1012161042b, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4481591542, createdName=wangaihua5399, createdTime=Sun May 01 18:40:50 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198861, encodeId=52fa1198861c7, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43525709658, createdName=ms6000000691333283, createdTime=Wed Mar 02 21:28:48 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189309, encodeId=8ea311893093c, content=积分不足了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41bf6155524, createdName=ms6000001446270839, createdTime=Sun Jan 30 16:06:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079362, encodeId=0a6410e936210, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/23c7fab364194717836769d96a50cdde/783e78a2b4a4410c9dae7e959ba1c77c.jpg, createdBy=1efd2552192, createdName=福尔摩妮, createdTime=Mon Dec 13 00:11:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078737, encodeId=421c10e8737c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d36395355, createdName=ms8000000249038546, createdTime=Fri Dec 10 11:59:25 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2021-12-10 ms8000000249038546

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 ABM临床方案#29：母乳喂养期间铁，锌和维生素D的补充

母乳喂养医学会(ABM,Academy of Breastfeeding Medicine) · 2018-07-30

2018 意大利共识：儿童时期维生素D补充

意大利儿科学会(Italian Pediatric Society) · 2018-05-08

2018 USPSTF建议声明：补充维生素，钙或联合补充作为社区成人骨折的一级预防

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2018-04-17

2017 JSBMR/JES评估标准：维生素D缺乏/不足

日本姑息医学会(JSPM,Japanese Society of Palliative Medicine) · 2017-01-01

维生素D与成年人骨骼健康应用指南（2014年标准版）

中国老年学学会骨质疏松委员会(OCCGS,Osteoporosis Committee of China Gerontological Society) · 2014-09-20

2014 ESCEO共识声明：膳食蛋白质和维生素D在维持绝经后妇女肌肉骨骼健康中的作用

欧洲骨质疏松和骨关节炎临床经济学会(ESCEO,The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) · 2014-07-17

拓展阅读

2011 ENDO维生素D缺乏症的评估、治疗和预防

美国内分泌学会(TES,The Endocrine Society) · 2011-06-06

2011EMAS 立场声明：维生素D和绝经后的健康

欧洲女性与男性更年期协会(EMAS,European Menopause and Andropause Society) · 2011-11-17

维生素矿物质补充剂在肿瘤防治中的临床应用：专家共识

中华医学会(CMA,Chinese Medical Association) · 2013-02-01

2013 ESCEO推荐建议：老年或绝经妇女补充维生素D（更新版）

欧洲骨质疏松和骨关节炎临床经济学会(ESCEO,The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) · 2013-02-07

2013USPSTF 成年人补充维生素D和钙补充剂防止骨折推荐声明

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2013-02-26

维生素矿物质补充剂在防治超重和肥胖中的临床应用：专家共识

中华医学会(CMA,Chinese Medical Association) · 2013-04-01